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Abstract
Staphylococcus aureus small-colony variants (SCVs) are being isolated more frequently in cystic ﬁbrosis (CF) patients. We aimed to deter-
mine the prevalence of S. aureus SCVs and their phenotypic and genotypic properties in CF patients admitted to a university hospital.
Specimens of 248 patients were examined during a period of 11 months. Colonies supposed to be SCVs were evaluated on Columbia
blood agar, mannitol salt agar, and brain–heart infusion agar with 5% NaCl (BHIA 5% NaCl). Strains were conﬁrmed by S. aureus nucA
PCR. Antibiotic susceptibilities of SCVs and simultaneously isolated S. aureus strains were determined for oxacillin, gentamicin, trimetho-
prim–sulphamethoxazole, vancomycin, ciproﬂoxacin, linezolid, and tigecycline. Genetic relatedness between SCVs and normal S. aureus
strains was determined with a pulsed-ﬁeld gel electrophoresis (PFGE) method. S. aureus SCVs were detected in 20 of 248 patients
(8.1%). The highest SCV isolation rate was obtained with MSA, followed by BHIA 5% NaCl. Auxotrophism for thymidine was demon-
strated in six SCVs. The tigecycline susceptibilities of 48 SCV strains isolated in this study showed higher MIC values than those of 33
simultaneously isolated normal S. aureus strains. Whereas SCVs and normal S. aureus strains showed identical genotypes in 14 of the
patients, ﬁve patients showed different genotypes. This ﬁrst study from Turkey evaluating S. aureus SCVs in CF patients has indicated
the importance of considering and reporting SCVs in chronic infections such as CF. The presence of SCVs will probably indicate persis-
tent infection, and this might impact on antibiotic treatment decisions, as they are more resistant to antibiotics.
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Introduction
Cystic ﬁbrosis (CF) patients are often colonized with Staphy-
lococcus aureus. The spectrum of microorganisms isolated
from the respiratory tract specimens of CF patients has
changed in recent years, and, as well as the frequent patho-
gens S. aureus and Pseudomonas aeruginosa, Burkholderia cepa-
cia complex, Stenotrophomonas maltophilia, Achromobacter
xylosoxidans and S. aureus small-colony variants (SCVs) are
being isolated more frequently [1–3]. S. aureus SCVs are
known as slow-growing subpopulations of S. aureus that
grow as small, non-pigmented and non-haemolytic colonies
on agar plates, and their isolation and identiﬁcation is a chal-
lenge for clinical microbiology laboratories [4]. This difﬁculty
may lead to diagnostic underestimation and therefore thera-
peutic failures in the clinical setting. S. aureus SCVs have
been associated with chronic and recurrent infections; how-
ever, this relationship has only been appreciated in recent
years [5,6].
The discovery and characterization of S. aureus SCVs have
provided new insights into our understanding of the patho-
genesis of chronic S. aureus lung infections in CF patients. As
SCVs can survive intracellularly, the isolation of an SCV phe-
notype is usually associated with the persistence of S. aureus
in CF patients. This study was aimed at determining the
prevalence and antibiotic susceptibility proﬁles of S. aureus
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SCVs in CF patients, identifying the best method for detec-
tion of SCVs in clinical specimens, and evaluating the genetic
relatedness between normal S. aureus strains isolated from
CF patients and their paired SCV strains.
Materials and Methods
This prospective study was conducted at Hacettepe University
Children’s Hospital, Chest Diseases Unit and Clinical Microbi-
ology Laboratory, Ankara, Turkey between February 2007 and
January 2008. Respiratory specimens of 248 CF patients were
screened for the presence of S. aureus SCVs. The specimens
comprised sputum and deep throat swab samples.
Specimens were cultured on Columbia sheep blood agar
(BD, Franklin Lakes, NJ, USA) and chocolate agar (Fluka,
Sigma-Aldrich, St. Louis, MO, USA) with 300 U/mL bacitracin
(Sigma-Aldrich, St. Louis, MO, USA), Eosin Methylene Blue
agar (Becton Dickinson), mannitol salt agar (MSA) (Becton
Dickinson), oxidation/fermentation polymyxin–bacitracin–
lactose agar, and brain–heart infusion agar (Oxoid, Basingstoke,
UK) with 5% NaCl (Merck, Darmstadt, Germany) (BHIA 5% -
NaCl). All agar plates were incubated at 35C for at least 48 h
aerobically, except for BHIA 5% NaCl plates, which were
incubated anaerobically.
Colonies suspected of being S. aureus on sheep blood agar,
MSA and BHIA 5% NaCl were further isolated at 35C for
24–48 h on Columbia sheep blood agar. Non-haemolytic,
non-pigmented, pinpoint or fried-egg colonies on sheep blood
agar and small colonies on MSA and BHIA 5% NaCl were
considered to be S. aureus SCVs. These suspected colonies
were inoculated onto Columbia blood agar and Schaedler agar
(Becton Dickinson). Columbia blood agar was incubated in a
normal atmosphere and Schaedler agar was incubated in 5–
10% CO2, both at 35C. If the colonies were observed to be
normal-sized, haemolytic and pigmented on Schaedler agar,
they were considered to be S. aureus SCVs. Strains were sub-
jected to species identiﬁcation by Gram staining, catalase
reaction, tube coagulase result, and latex agglutination test
(Slidex Staph Plus; bioMe´rieux, Marcy l’Etoile, France). Identi-
ﬁcation of S. aureus was conﬁrmed by nucA PCR [7].
Auxotrophy for haemin (5.4 lg) was tested by using
standard disks (Sigma), and auxotrophy for thymidine and
menadione was tested by impregnating disks with 1.5 lg of
thymidine (Sigma) or 1.5 lg of menadione (Sigma), respec-
tively. A strain was positive for auxotrophy if a zone of
growth surrounding the impregnated disks on Mueller–Hinton
agar was detected after 24 h of incubation at 35C [8,9].
Antimicrobial susceptibilities of the strains were
determined by the broth microdilution method for oxacillin,
gentamicin, vancomycin, ciproﬂoxacin, linezolid, trimetho-
prim–sulphamethoxazole and tigecycline according to CLSI
guidelines [10]. Strains with a normal phenotype were tested
on Mueller–Hinton broth, and SCVs were tested on brain–
heart infusion broth [11]. The MIC values of SCVs were
evaluated according to CLSI breakpoints for staphylococci
[12]. As there are no CLSI criteria for tigecycline, EUCAST
susceptibility criteria were applied [13].
Clonal identity and genetic relatedness between normal
S. aureus strains and their paired SCVs were analysed with a
pulsed-ﬁeld gel electrophoresis (PFGE) method after SmaI
(Sigma) restriction of bacterial DNA, as described previously
[14]. The 33 normal S. aureus strains selected for PFGE were
the pairs of related SCVs isolated from each patient. The
PFGE bands produced were evaluated according to the
Tenover criteria [15]. PFGE genotypes were numbered sepa-
rately within each patient. No interpatient genetic related-
ness analysis was performed.
Clinical data of patients with SCV isolation were collected
and evaluated from patients’ medical records by the physi-
cians of the paediatric chest diseases unit. Statistical analysis
was performed with SPSS software, version 15.0. Deﬁnitive
statistics were represented as means, medians, and percent-
ages. Differences between means were evaluated with the
Mann–Whitney test for the numerical variables and the chi-
square, Mantel–Haenzel or Fisher exact test for the categori-
cal variables. A p-value cut-off of £0.05 was considered to be
statistically signiﬁcant for all analyses.
Results
A total of 519 respiratory specimens from 248 CF patients
were evaluated for the presence of S. aureus SCVs. Of these
519 specimens, 209 (40.3%) were sputum and 310 (59.7%)
were deep throat swab samples. The number of male
patients (129, 52%) was similar to the number of female
patients (119, 48%). The median age of patients was
9.9 years (range: 1–58 years), and was similar in the two
genders (Table 1).
Of the 248 patients, 123 (49.6%) harboured normal
S. aureus strains in their respiratory specimens, and 20
(8.1%) harboured SCVs as well. The prevalence of SCVs in
S. aureus-positive patients was 16.2% (20/123). Of these 20
SCV-positive patients, 13 (65%) were females and seven
were males. The median age of patients with normal
S. aureus strains was 10.4 years (range: 1–58 years), and that
of patients with SCVs was 14.4 years (range: 2–31 years);
the isolation rate was highest in those between 11 and
15 years of age, who constituted a total of 25% of the
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patients (p <0.05). Patients with SCVs were older than
patients with normal S. aureus strains only (p 0.015, Mann–
Whitney U-test) (Table 1). Among the 20 SCV carriers, 13
had SCVs once, two had SCVs twice, and ﬁve had SCVs
three times. Persistent colonization was deﬁned as three or
more positive cultures during the study period, and was
demonstrated in 25% (n = 5) of SCV carriers. From these 20
patients, 48 SCVs and 30 normal S. aureus strains were iso-
lated in a total of 32 samples. Fifteen (46.9%) of these 32
samples also revealed the simultaneous presence of P. aeru-
ginosa and S. aureus SCVs.
The review of patients’ medical reports revealed that no
antistaphylococcal prophylaxis had been given to the patients.
The most frequently used antibiotics for the staphylococcal
infections in CF patients were amoxycillin–clavulanate, ampi-
cillin–sulbactam, and ﬂuoroquinolones. Trimethoprim–sulpha-
methoxazole was used in only ﬁve patients and gentamicin in
four patients. All of the ﬁve patients with SCVs with trimeth-
oprim–sulphamethoxazole resistance had been treated with
trimethoprim–sulphamethoxazole. The length of the treat-
ment varied from 1 month to 2 years for different patients.
The trimethoprim–sulphamethoxazole-resistant SCVs from
these ﬁve patients were thymidine-dependent SCVs (Table 2).
Of the 48 SCVs, 28 were isolated after an incubation per-
iod of 24 h and 20 after an incubation period of 48 h. The
highest SCV yield was from MSA (66.7%), followed by
BHIA 5% NaCl (50%). For patients infected or colonized
with SCVs, a reliable bacterial count could not be obtained,
as they grow as tiny colonies and are usually covered by nor-
mal S. aureus colonies. Typical small colonies were observed
for 36 (75%) of strains (Fig. 1). Six strains (12.5%) formed
pinpoint colonies and six (12.5%) formed fried-egg colonies.
Among the 48 SCVs, six were thymidine-dependent
(Fig. 2). Of these six, one was also haemin-dependent. Five
of the thymidine-dependent strains formed fried-egg colo-
nies. No menadione-dependent strains were detected.
The resistance rates of SCVs were as follows: oxacillin,
10.4%; trimethoprim–sulphamethoxazole, 16.7%; ciproﬂoxacin,
14.6%; and gentamicin, 6.3%. When compared with those for
simultaneously isolated normal S. aureus strains, these resis-
tance rates showed no signiﬁcant difference. No resistance
was detected for vancomycin and linezolid. MICs for tigecy-
line were signiﬁcantly higher for SCVs than for simulta-
neously isolated normal S. aureus strains (p 0.041, Fisher)
(Table 3).
A total of 81 strains (33 normal S. aureus strains and 48
paired SCVs) were genotyped by PFGE (Fig. 3). PFGE bands
of S. aureus and SCV strains with the same proﬁle were con-
sidered to indicate clonality [15]. Whereas SCVs and their
normal counterparts showed clonality in 14 of the patients,
ﬁve patients exhibited different genotypes for SCV and nor-
mal strains. One patient exhibited different SCV genotypes
and also different normal S. aureus genotypes in a single sam-
ple. Persistence of the same SCV was seen in ﬁve patients.
Discussion
This is the ﬁrst study to demonstrate the prevalence and
phenotypic and genotypic characteristics of S. aureus SCVs in
CF patients in Turkey. The prevalence of S. aureus coloniza-
tion in our CF centre, which is the reference CF centre in
Turkey, was 57.7% during the study period. The US Patient
Registry Annual Data Report 2009 indicated that the S. aur-
eus prevalence in CF patients was 51.3% [16]. The European
CF S. aureus prevalence varies between 60.6% and 72% in
different CF centres (UK, Germany, Belgium, and France)
[1,17,18]. SCVs were isolated from 8.1% of CF patients and
6.4% of specimens evaluated. Among S. aureus-positive
patients, the prevalence was 16.2%. In the study of Besier
et al., respiratory specimens of 252 CF patients in Germany
were evaluated, and the SCV prevalence was found to be
17% among S. aureus carriers, which is similar to our ﬁnd-
ings. The median age of our patient population was 9.9 years,
and that of the SCV-positive patients was 14.4 years. The
median age of CF patients in Besier’s study was 16 years,
and of the SCV-positive patients was 21 years [9]. Kahl et al.
[11] reported a high prevalence (49.1%) of SCVs in their
S. aureus-positive CF population, in which the median age of
SCV-positive patients was 13 years, and all SCV-positive
patients received long-term trimethoprim–sulphamethoxaz-
ole prophylaxis. In one recent study, SCV prevalence was
reported to be 8.2%, similar to our ﬁndings. However, the
authors focused on only one respiratory specimen per
patient in a short period [10]. The emergence of S. aureus
SCVs has been reported to be associated with antibiotic use,
but isolation after extended antibiotic-free intervals may also
be possible [6,19]. The median ages of our patient population
TABLE 1. Comparison of the ages of patients with normal
Staphylococcus aureus and the ages of patients with S. aureus
small-colony variants (SCVs)
Age (years)
Patients with
normal S. aureus
Patients with
S. aureus SCVs
n (%) n (%)
1.0–5.0 42 (34.1) 3 (15.0)
6.0–10.0 31 (25.2) 4 (20.0)
11.0–15.0 23 (18.7) 5 (25.0)
16.0–20.0 17 (13.8) 3 (15.0)
21.0–25.0 5 (4.1) 4 (20.0)
‡26.0 5 (4.1) 1 (5.0)
Total 123 (100.0) 20 (100.0)
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TABLE 2. Genetic diversity of Staphylococcus aureus small-colony variants (SCVs) and paired S. aureus strains from 20 patients
harbouring S. aureus SCVs
Patient no. Date of admission Phenotype PFGE genotype OX GM VA CIP LZ SXT TG
1 6 March 2007 SCV II R R S R S R R
16 March 2007 SCV II R R S R S S S
S. aureus I S S S S S S S
2 17 April 2007 SCV I S S S I S S S
SCV I S S S S S R S
S. aureus III S S S S S S S
3 August 2007 SCV I S S S S S S S
SCV I S S S I S S S
SCV I S S S I S S S
19 November 2007 S. aureus IV S S S S S S S
SCV II R S S S S S S
3 18 April 2007 S. aureus I S S S S S S S
SCV I S S S I S S S
4 26 April 2007 S. aureus I R S S I S S S
SCV I S S S S S S S
7 June 2007 S. aureus I S S S S S S S
SCV I S S S S S S S
17 December 2007 S. aureus I S S S S S S S
S. aureus I R S S S S S S
SCV I S I S S S S R
SCV I S S S S S S R
5 30 March 2007 S. aureus I S S S S S S S
SCV I S S S S S S S
24 October 2007 S. aureus I R S S S S S S
SCV I R S S S S S S
11 December 2007 S. aureus I S S S S S S S
SCV I R S S S S S S
SCV I R S S S S S S
SCV I S S S S S S R
6 5 June 2007 SCV I S S S I S S S
SCV I S S S S S S S
SCV I R S S I S S S
S. aureus I S S S I S S S
26 September 2007 SCV I S S S I S S S
17 January 2008 S. aureus I S S S I S S S
SCV I S S S I S S S
7 5 June 2007 S. aureus I S S S R S S S
SCV I S S S I S S S
8 5 June 2007 S. aureus I S S S R S S S
SCV I S S S S S S S
9 27 June 2007 S. aureus II S S S I S S S
SCV I S S S I S R S
17 August 2007 S. aureus II S S S S S R S
SCV I S S S R S S S
8 October 2007 S. aureus II R S S S S S S
S. aureus I S S S I S S S
SCV I R S S S S S S
10 4 July 2007 S. aureus II R S S S S S S
S. aureus II R S S S S S S
S. aureus I S S S S S S S
SCV – R S S S S R S
SCV I R S S S S R S
SCV II R S S S S R S
SCV I S S S S S R S
11 27 June 2007 S. aureus I S S S S S S S
SCV I R S S S S S S
SCV I S S S S S S S
12 3 August 2007 S. aureus I S S S R S S S
SCV I R S S I S S S
13 22 August 2007 SCV I S S S S S S S
SCV I S S S S S S S
S. aureus I S S S I S S S
14 1 October 2007 S. aureus I R S S R S S S
SCV I R S S R S S S
7 January 2008 S. aureus I R S S R S S S
SCV I R S S R S S R
15 16 October 2007 S. aureus I S S S S S S S
SCV I S S S S S S S
16 15 November 2007 S. aureus I R S S S S S S
SCV I S S S S S S S
SCV I S S S S S S S
17 11 December 2007 S. aureus I R S S S S S S
S. aureus I S S S S S S S
SCV I S S S S S S S
18 10 December 2007 SCV I R S S S S S R
SCV I S S S S S S S
19 29 November 2007 S. aureus I S S S R S S S
SCV S S S S S S S
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seemed to be lower than that mentioned in the studies of
Besier and Kahl, and it was also determined that no trimeth-
oprim–sulphamethoxazole prophylaxis had been applied in
our CF population. The lower SCV prevalence in our study
group might be attributable to these two factors.
S. aureus colonization is highest in infants and young chil-
dren with CF [20]. However, the emergence of SCVs was
found to be associated with advanced age, and the reason
might be the increased consumption of antibiotics with
increasing age [9,17]. This relationship was also observed in
our study.
It is well documented that the use of MSA for the recov-
ery of S. aureus is a prerequisite for CF microbiology [21]. In
a multicentre survey from Belgium, SCV prevalence was
found to be lower (4%) than in other studies; however, the
authors indicated that almost all SCVs were recovered from
patients in a single laboratory, which processed specimens
from two centres. It was also indicated that appropriate
techniques were not used in most centres, so they failed to
detect any SCVs [17]. In this study, all SCVs were initially
detected in MSA plates, allowing proper isolation and further
identiﬁcation. According to our study, the best method for
detecting SCVs was to inoculate specimens onto both MSA
and BHIA 5% NaCl as well as Columbia blood agar. When
MSA and BHIA 5% NaCl were used together, detection and
identiﬁcation of 86.6% of SCVs were achieved. These selec-
tive media suppress the growth of P. aeruginosa and support
TABLE 2. Continued
Patient no. Date of admission Phenotype PFGE genotype OX GM VA CIP LZ SXT TG
20 31 January 2008 S. aureus I S S S S S S S
SCV II R S S R S R S
SCV II R R S R S S S
PFGE, pulsed-ﬁeld gel electrophoresis; OX, oxacillin; GM, gentamicin; VA, vancomycin; CIP, ciproﬂoxacin; LZ, linezolid; SXT, trimethoprim–sulphamethoxazole; TG, tigecy-
cline; R, resistant; I, intermediate; S, sensitive.
PFGE genotypes are numbered separately for each patient. No interpatient genetic relatedness analysis was performed.
FIG. 1. Staphylococcus aureus small-colony
variants (black arrow) and normal S. aureus
colonies (red arrow) on mannitol salt agar
(left) and brain–heart infusion agar with 5%
NaCl (right).
FIG. 2. Thymidine-dependent Staphylococcus aureus small-colony vari-
ants on Mueller–Hinton agar. H, haemin; M, menadione; T, thymidine.
TABLE 3. Antibiotic susceptibilities of Staphylococcus aureus small-colony variants (SCVs) and paired normal S. aureus strains
Antibiotic
S. aureus (n = 33) S. aureus SCV (n = 48)
MIC range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L) R (%)a
MIC range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L) R (%)a
Oxacillin £0.06–2 0.25 1 – £0.06 to >64 0.25 4 5 (10.4)
Gentamicin £0.125–4 1 4 – £0.125 to >128 1 4 4 (8.4)
Vancomycin 0.25–2 1 2 – 0.125–2 1 2 –
Ciproﬂoxacin 0.25 to >32 0.5 4 27 (81.8) 0.03 to >32 1 16 37 (77.1)
Linezolid 0.25–4 2 4 – 0.25–4 2 2 –
TMP-SXT 0.016–32 0.125 0.25 1 (3.0) 0.023 to >32 0.25 32 8 (16.7)
Tigecyclineb 0.015–0.5 0.125 0.25 – 0.015–2 0.06 1 6 (12.5)
R, resistant; TMP-SXT, trimethoprim–sulphamethoxazole.
aIntermediate strains were included in the resistant category.
bAccording to EUCAST breakpoints.
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the growth of normal S. aureus and SCVs [11]. Thus, MSA
together with BHIA 5% NaCl could be an appropriate choice
for SCV isolation, especially in laboratories with fewer
facilities.
P. aeruginosa strains in CF patients produce 4-hydroxy-2-
heptylquinoline-N-oxide, which suppresses the growth of
S. aureus, and prolonged exposure causes the emergence of
S. aureus SCVs [22–24]. Besier et al. reported that co-coloni-
zation with P. aeruginosa was signiﬁcantly more frequent in
patients with S. aureus SCVs than in patients with normal
S. aureus only [9]. We found that 50% patients with S. aureus
SCVs (10 of 20 patients) were co-colonized with P. aerugin-
osa, whereas only 28.56% (30 of 105) of patients with normal
S. aureus were simultaneously positive for P. aeruginosa.
However, the difference between the groups was not signiﬁ-
cant in our study.
Lack of biosynthesis of menadione or haemin occurs in
electron transport-deﬁcient SCVs, and this phenotype can be
reversed by supplementation of media with menadione or
haemin. Nonetheless, SCVs without auxotrophism for thymi-
dine, menadione or haemin were reported to be CO2-depen-
dent [4,25]. Auxotrophism for thymidine was detected in a
small number of SCVs in our study as compared with the
results of some previous studies. Auxotrophism was reported
for haemin in 10 strains, for menadione in two strains and for
thymidine in 41 strains among 78 S. aureus SCVs by Kahl et al.
However, the selection of these auxotrophic strains was
attributed to long-term trimethoprim–sulphamethoxazole
prophylaxis or interventional aminoglycoside treatment [11].
In another study, thymidine auxotrophism was detected in
63% of the strains [9]. The lower number of auxotrophic
strains detected in our study might be attributable to the fact
that there is no antistaphylococcal prophylaxis and no pre-
dominant use of aminoglycoside treatment in cases of staphy-
lococcal lung disease in our centre. Also, the SCV phenotype
of our strains might also be attributable to CO2 auxotro-
phism, which we could not detect. Another possible explana-
tion could be the reversion of some of the strains during
auxotrophism testing on Mueller–Hinton agar. Besides MHA,
several other media, such as chemically deﬁned medium
(CDM) or tryptic soy agar, were used in previous studies
[5,11]. Further studies are needed to determine which media
are best for testing auxotrophism in S. aureus SCVs.
As S. aureus SCVs grow slowly, they have decreased sus-
ceptibility to cell wall-active antibiotics [26,27]. In vitro and
in vivo selection of mutants that are more resistant to cipro-
ﬂoxacin among clinical S. aureus SCVs has been reported
before [9,28,29]. Thus, it is not surprising that the number
of strains that were resistant/intermediately resistant to cip-
roﬂoxacin was higher than the number that were resistant/
intermediately resistant to the other antibiotics among nor-
mal S. aureus and SCV strains, as ﬂuoroquinolones have been
used predominantly in our study population. All of the thymi-
dine-dependent strains that formed fried-egg colonies were
resistant to trimethoprim–sulphamethoxazole in our study,
in agreement with previous studies [1]. Although S. aureus
SCVs were found to be more antibiotic-resistant than their
simultaneously isolated counterparts, no signiﬁcant difference
was detected, probably because of the small number of
strains tested.
The intracellular activity of tigecycline was evaluated in an
infected cell model, and no higher activity was observed
against SCV strains than against normal or revertant pheno-
types [23]. To the best of our knowledge, our study is the
ﬁrst to show that MIC values for tigecyline were signiﬁcantly
higher in SCVs than in the simultaneously isolated normal
S. aureus strains. Tigecycline resistance among S. aureus
strains is very rare [13]. Consistent with the literature, we
did not detect any resistance among normal S. aureus strains.
However, the noteworthy ﬁnding of our study is that resis-
tant strains are SCVs.
FIG. 3. Pulsed-ﬁeld gel electrophoresis patterns (SmaI digest).
Lanes 1 and 2: patient 14 (small-colony variants (SCVs)). Lane 3:
patient 20 (normal Staphylococcus aureus). Lanes 4 and 5: patient 20
(SCVs). Lane 6: patient 8 (normal S. aureus). Lane 7: patient 8
(SCVs). Lanes 8 and 9: patient 10 (normal S. aureus). Lanes 10, 11,
13, and 14: patient 2 (SCVs). Lane 12: patient 2 (normal S. aureus).
M: molecular marker.
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Genotyping by PFGE revealed clonality between S. aureus
SCVs and simultaneously isolated normal S. aureus strains in
a group of patients. However, some of the patients har-
boured different clones. When consecutive strains of
patients were analysed longitudinally, it was observed that
S. aureus strains in some patients could transform into differ-
ent genotypes. The persistence of a predominant clone in a
patient might indicate prevention of colonization by other
lineages in the airways of patients, probably because of bac-
terial interference. Although SCVs and normal S. aureus
strains have a tendency to persist in CF airways, transient/
persistent colonization by another clone could be possible.
Similar observations have been made for persistent P. aeru-
ginosa colonization in CF patients [30,31].
This ﬁrst study to evaluate S. aureus SCVs in CF patients
in Turkey indicated the need for proper isolation, identiﬁca-
tion and reporting of S. aureus SCVs in the CF population, as
the presence of S. aureus SVCs in airways will probably indi-
cate adaptation of bacteria in airways and persistent infec-
tion. This information might have an impact on antibiotic
treatment decision-making, as SCVs tend to resist intracellu-
lar killing and are more resistant to antibiotics.
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